{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:39:30Z","timestamp":1789594770692,"version":"build-2803163510"},"reference-count":22,"publisher":"Hindawi Limited","issue":"5","license":[{"start":{"date-parts":[[2012,6,7]],"date-time":"2012-06-07T00:00:00Z","timestamp":1339027200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2012,6,7]],"date-time":"2012-06-07T00:00:00Z","timestamp":1339027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1111\/j.1365-2710.2012.01349.x","type":"journal-article","created":{"date-parts":[[2012,6,8]],"date-time":"2012-06-08T02:23:14Z","timestamp":1339122194000},"page":"578-587","source":"Crossref","is-referenced-by-count":23,"title":["Safety, tolerability and pharmacokinetics after single and multiple doses of preladenant (SCH420814) administered in healthy subjects"],"prefix":"10.1155","volume":"37","author":[{"given":"D. L.","family":"Cutler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tendolkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. D.","family":"Grachev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2012,6,7]]},"reference":[{"key":"10.1111\/j.1365-2710.2012.01349.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson\u2019s disease","volume":"5","author":"de Lau","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1111\/j.1365-2710.2012.01349.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0165-6147(97)90660-X","article-title":"Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson\u2019s disease","volume":"18","author":"Richardson","year":"1997","journal-title":"Trends Pharmacol Sci"},{"key":"10.1111\/j.1365-2710.2012.01349.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ncl.2009.04.009","article-title":"Medical treatment of Parkinson disease","volume":"27","author":"Stacy","year":"2009","journal-title":"Neurol Clin"},{"key":"10.1111\/j.1365-2710.2012.01349.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"S548","DOI":"10.1002\/mds.22062","volume":"23","author":"Obeso","year":"2008","journal-title":"Mov Disord"},{"key":"10.1111\/j.1365-2710.2012.01349.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/0166-2236(90)90107-L","article-title":"Functional architecture of basal ganglia circuits: neural substrates of parallel processing","volume":"13","author":"Alexander","year":"1990","journal-title":"Trends Neurosci"},{"key":"10.1111\/j.1365-2710.2012.01349.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.parkreldis.2008.12.006","article-title":"Adenosine, adenosine A2A antagonists, and Parkinson\u2019s disease","volume":"15","author":"Jenner","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1111\/j.1365-2710.2012.01349.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.pneurobio.2007.05.001","article-title":"Adenosine A2A receptors and basal ganglia physiology","volume":"83","author":"Schiffmann","year":"2007","journal-title":"Prog Neurobiol"},{"key":"10.1111\/j.1365-2710.2012.01349.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/1096-9861(20010312)431:3<331::AID-CNE1074>3.0.CO;2-W","article-title":"Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum","volume":"431","author":"Hettinger","year":"2001","journal-title":"J Comp Neurol"},{"key":"10.1111\/j.1365-2710.2012.01349.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/157488907779561772","article-title":"Blocking striatal adenosine A2A receptors: a new strategy for basal ganglia disorders","volume":"2","author":"Muller","year":"2007","journal-title":"Recent Pat CNS Drug Discove"},{"key":"10.1111\/j.1365-2710.2012.01349.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/(SICI)1098-2396(199602)22:2<132::AID-SYN6>3.0.CO;2-E","article-title":"Opposing actions of adenosine A2a and dopamine D2 receptor activation on GABA release in the basal ganglia: evidence for an A2a\/D2 receptor interaction in globus pallidus","volume":"22","author":"Dayne","year":"1996","journal-title":"Synapse"},{"key":"10.1111\/j.1365-2710.2012.01349.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1212\/01.WNL.0000095211.71092.A0","article-title":"Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists","volume":"61","author":"Mori","year":"2003","journal-title":"Neurology"},{"key":"10.1111\/j.1365-2710.2012.01349.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1046\/j.1471-4159.2003.01632.x","article-title":"Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of L-DOPA-induced dyskinesia","volume":"84","author":"Lundblad","year":"2003","journal-title":"J Neurochem"},{"key":"10.1111\/j.1365-2710.2012.01349.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1212\/WNL.52.8.1673","article-title":"Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys","volume":"52","author":"Grondin","year":"1999","journal-title":"Neurology"},{"key":"10.1111\/j.1365-2710.2012.01349.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ana.410430415","article-title":"Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys","volume":"43","author":"Kanda","year":"1998","journal-title":"Ann Neurol"},{"key":"10.1111\/j.1365-2710.2012.01349.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1124\/jpet.108.149617","article-title":"Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression","volume":"330","author":"Hodgson","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1365-2710.2012.01349.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0014-2999(97)83039-7","article-title":"Adenosine A2 receptors modulate haloperidol-induced catalepsy in rats","volume":"328","author":"Mandhane","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"10.1111\/j.1365-2710.2012.01349.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s002130051146","article-title":"Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP","volume":"147","author":"Shiozaki","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1111\/j.1365-2710.2012.01349.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.bmcl.2006.11.083","article-title":"Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines","volume":"17","author":"Neustadt","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1111\/j.1365-2710.2012.01349.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1474-4422(11)70012-6","article-title":"Preladenant in patients with Parkinson\u2019s disease and motor fluctuations: a phase 2, double-blind, randomised trial","volume":"10","author":"Hauser","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1111\/j.1365-2710.2012.01349.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.bjp.0703045","article-title":"A2A adenosine receptors in human peripheral blood cells","volume":"129","author":"Gessi","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1111\/j.1365-2710.2012.01349.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0306-4522(99)00473-X","article-title":"Localization and action of adenosine A2a receptors in regions of the brainstem important in cardiovascular control","volume":"95","author":"Thomas","year":"2000","journal-title":"Neurosci"},{"key":"10.1111\/j.1365-2710.2012.01349.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00415-008-5004-3","article-title":"Epidemiology of Parkinson\u2019s disease","volume":"255","author":"Alves","year":"2008","journal-title":"J Neurol"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2710.2012.01349.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2710.2012.01349.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2710.2012.01349.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:04:29Z","timestamp":1671818669000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2710.2012.01349.x"}},"subtitle":["Safety, tolerability and pharmacokinetics of preladenant"],"short-title":[],"issued":{"date-parts":[[2012,6,7]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,10]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2710.2012.01349.x","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6,7]]}}}